No access in your country to PARPi for mCRPC with DNA repair alterations? 💊 Platinum agents can work, especially in BRCA-altered mCRPC. Screen your patients. Affordable options exist!

🚨 New paper alert👉🏼Pleased to share IASLC #MTB recommendations in JTO & JTO CRR! Kudos to the amazing Mihaela Aldea for integrating so many inputs (just look at the author list, has so many awesome colleagues in #LungCancer #PrecisionOncology). This paper shapes a framework

My lab (kather.ai) will soon be looking for multiple postdocs / research software engineers in the field of agentic AI in cancer research. Our team recently published the first tumor board agent and we are planning to scale this up nature.com/articles/s4301… Other

🤖 #ESMOAI25: Responsible innovation starts here! Present your research and help us drive the evolution of AI and digital solutions in oncology ⏰ Submit your abstract by 2 September 2025 #HealthAI 🔗 ow.ly/6V7250WgJIk

Are we ready for ultra-precision oncology? 🔬✨ 📖 New online: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC doi.org/10.1158/1078-0… (with Federica Pecci Biagio Ricciuti, MD, PhD Alfredo Addeo MD

Precision oncology keeps getting more precise 🔬✨ 🚨Just published in Clinical Cancer Research our study: First-line MET TKIs vs immunotherapy ± chemotherapy in #METex14 #NSCLC ✦ ICI±chemo showed benefit in tumors with very high PD-L1 ✦ MET TKIs extended survival in patients with lower

Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver. Mihaela Aldea shows incidence, highest in ALK/RET/EGFR/ROS1. AMG193 paved the way at #ESMO24. BMS-986504 confirms druggability: 29% ORR + many durable SD (slide Charu Aggarwal, MD, MPH, FASCO). #WCLC25

🤖 #ESMOAI25: Your not to miss sessions! Multimodal AI for clinical decision support, featuring discussions about assistants for molecular tumour boards, multimodal integration and more! Register by 22 October and benefit from advantageous fees #HealthAI 🔗

A #multinational effort 🌎 involving over 110 patients investigating the selective #RETinhibitor 💊#BOS172738. Whilst manageable safety profile and promising efficacies were shown, drug was chosen not to be further developed due to already competitive landscape. Thanks

🤖 #ESMOAI25: Your not-to-miss sessions! Digital technologies in the real world of oncology, featuring discussions on how digital health is transforming care pathways, clinical research and more! #HealthAI ⏰ Register by 22 October and benefit from advantageous fees 🔗

Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care nej.md/3HDriLB #Hematology

🤖 How can multimodal AI support #PrecisionOncology? At #ESMOAI25, the session “Multimodal AI for clinical decision support” will explore tumour boards, real-world data, explainability & integration challenges. 👉esmo.org/meeting-calend… #ESMOAI25 #DigitalOncology #HealthAI

🤖 #ESMOAI25: Your not-to-miss sessions! Clinical trials for AI and AI for clinical trials, featuring discussions on applications in breast cancer, pathology and more! ⏰ Register by 22 October and benefit from advantageous fees. #HealthAI #esmomeetings 🔗

🤖 #ESMOAI25: Your not-to-miss sessions! AI to unlock the data vault, featuring discussions on foundation models for radiology, EHRs with AI and more! ⏰ Register by 22 October and benefit from advantageous fees #HealthAI 🔗 ow.ly/L8Yr50X5EtQ

The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively. #ESMOAI25 #ESMO25 #LLMs #HealthAI 🔗ow.ly/W3zX50XeukF

📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC Meimei Zheng bit.ly/3J5dlqk

Definitely wow!

🤖 AI is only as good as the data it learns from At #ESMOAI25 the session “AI to unlock the data vault” will discuss how data structuring and harmonisation pave the way for effective AI applications in oncology. 👉esmo.org/newsroom/esmo-… #DigitalOncology #AIOncology #HealthAI

🤖 AI is accelerating #CancerDiagnostics - improving both speed and accuracy. 👉 Learn more in the session “AI-based biomarkers for precision oncology” at #ESMOAI25 in Berlin. esmo.org/meeting-calend… #DigitalOncology #PrecisionOncology #HealthAI

#ESMOAI25: Explore the latest AI-driven innovations in #oncology, brought to you by the #ESMOAmbassadors. Join the conversation on digital transformation in #CancerCare. #HealthAI 🔗 ow.ly/4V6z50XkYE6